Loading...
01/11 03:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
Revenue (Consolidated) $2.681 billion, up 7% on a reported basis and 5% on an organic basis year-over-year. Growth attributed to strong performance across segments.
Adjusted Gross Margin 72.7%, a decrease of 40 basis points year-over-year. No specific reason for the decrease mentioned.
Adjusted Operating Expenses $1.024 billion, an increase of $41 million year-over-year. No specific reason for the increase mentioned.
Adjusted EBITDA (Consolidated) $986 million, an increase of $77 million or 8% year-over-year. Growth attributed to operational performance.
Adjusted Operating Cash Flow (Consolidated) $508 million. No year-over-year change or reason mentioned.
Revenue (Bausch Health excluding Bausch + Lomb) $1.4 billion, up 7% on a reported basis and 5% on an organic basis year-over-year. Growth attributed to strong performance in Solta and Salix businesses.
Adjusted EBITDA (Bausch Health excluding Bausch + Lomb) $773 million, up 7% year-over-year, including an $81 million R&D charge. Excluding the charge, adjusted EBITDA grew 18% year-over-year.
Adjusted Operating Cash Flow (Bausch Health excluding Bausch + Lomb) $347 million, up 1% year-over-year. Limited growth due to timing in working capital.
Revenue (Salix) $716 million, up 12% on a reported basis and 11% on an organic basis year-over-year. Growth driven by Xifaxan volume growth and one-time net pricing favorability.
Revenue (International Segment) $286 million, down 2% on a reported basis and 4% on an organic basis year-over-year. Decline due to market softness in Mexico and nonrecurrence of Wellbutrin orders in Canada.
Revenue (Solta Medical) $140 million, up 25% on a reported basis and 24% on an organic basis year-over-year. Growth driven by strong performance in the Asia Pacific region, particularly South Korea.
Revenue (Diversified Segment) $258 million, down 4% on a reported basis and 6% on an organic basis year-over-year. Decline driven by nonrecurrence of prior year orders for Cardizem and challenges in neurology.
Revenue (Bausch + Lomb) $1.3 billion, up 7% on a reported basis and 6% on an organic basis year-over-year. Growth attributed to strong performance across the segment.
Cabtreo: Achieved triple-digit growth and became the #1 prescribed topical branded acne product in new brand patient starts. 105,000 new patients prescribed year-to-date, up 69% over the prior year.
Ryaltris: Achieved triple-digit growth.
Xifaxan: Delivered double-digit growth, with a 16% revenue increase in Q3. 71,000 new patients started in Q3, up 14% year-over-year.
Thermage: Received medical device licensing clearance in Canada and surpassed 1,000 unit installed base milestone in Korea.
Fraxel FTX: Launched in April 2025 in the U.S. with global expansion planned.
Solta Medical: Achieved 25% revenue growth, driven by strong performance in South Korea (96% growth) and double-digit growth in the U.S., EMEA, and Canada.
Salix: Achieved 12% revenue growth, driven by Xifaxan volume growth and favorable pricing.
Revenue Growth: Bausch Health (excluding Bausch + Lomb) achieved 7% revenue growth on a reported basis and 5% on an organic basis.
Debt Reduction: Reduced debt by $600 million using cash on hand.
Adjusted EBITDA: Grew 7% year-over-year, or 18% excluding a $81 million R&D charge.
DURECT Acquisition: Acquired DURECT Corporation, adding larsucosterol to the R&D pipeline for treating alcohol-associated hepatitis (AH). Phase III study planned for early 2026.
RED-C Development: Continued progress on two global Phase III studies for RED-C, targeting overt hepatic encephalopathy, with data expected by early 2026.
Macroeconomic Environment: Uncertainty in the macroeconomic environment, particularly in China, has led to cautious consumer behavior in the aesthetics market, potentially impacting revenue growth.
Geographic Performance Variability: Mixed performance in international markets, with declines in Canada and Latin America due to factors like market softness in Mexico and reduced orders for certain products.
Payer Coverage Challenges: Relistor continues to face a challenging payer coverage environment, which could hinder its growth potential.
Revenue Dependence on Key Markets: Solta's revenue is heavily dependent on the Asia Pacific region, particularly South Korea, which could pose risks if demand in this region declines.
Regulatory and R&D Risks: The development of new treatments like larsucosterol and RED-C involves significant R&D investment and regulatory hurdles, with no guarantee of successful commercialization.
Debt and Capital Structure: Despite reducing debt by $600 million, the company still faces challenges in optimizing its capital structure and managing long-term financial obligations.
Product-Specific Risks: The dermatology segment's growth is partly driven by new products like Cabtreo, which may face competitive pressures or market adoption challenges.
Revenue Guidance: The company has raised its full-year revenue guidance to be between $5 billion and $5.1 billion, reflecting a midpoint increase of $25 million and a 4% year-over-year growth.
Adjusted EBITDA Guidance: The adjusted EBITDA outlook has been increased to a range of $2.7 billion to $2.75 billion, excluding the impact of core IP R&D, representing a 7% increase compared to 2024.
Adjusted Operating Cash Flow Guidance: The adjusted operating cash flow is now expected to be between $975 million and $1.025 billion, with the midpoint raised by $150 million.
Xifaxan Growth: Xifaxan's growth is expected to continue, driven by both volume and price increases across all indications, supported by enhanced marketing and AI-driven customer insights.
Solta Medical Segment: The Solta Medical segment is anticipated to maintain its growth trajectory, with significant contributions from the Asia Pacific region and expansion in the U.S. and European markets. New product launches, such as Fraxel FTX, are expected to drive future growth.
DURECT Acquisition and Pipeline: The acquisition of DURECT Corporation adds larsucosterol to the R&D pipeline, with a Phase III study for alcohol-associated hepatitis planned to begin by early 2026. This is expected to enhance the company's hepatology portfolio.
RED-C Development: The company is on track with two global Phase III studies for RED-C, a potential next-generation treatment for overt hepatic encephalopathy, with initial data readouts expected by early 2026.
The selected topic was not discussed during the call.
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
The earnings call presents a mix of positive and neutral factors. Strong financial performance, including revenue and EBITDA growth, and positive developments in product segments like Salix and Solta Medical, contribute to a positive outlook. However, concerns over the IRA impact on Xifaxan and limited details on the DURECT acquisition introduce some uncertainty. The shift away from share buybacks could be seen as a negative, but overall, the positive financial metrics and strategic focus on growth suggest a positive stock movement in the short term.
The earnings call presents mixed signals: financial results show modest revenue growth and debt reduction, but margins have declined and refinancing increased costs. The guidance is optimistic, yet management's vague responses in Q&A raise concerns. The market cap suggests a moderate reaction. Overall, the sentiment is neutral, with no strong catalysts to drive significant stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
